News & Updates

Use of selexipag shows promise in the treatment of systemic sclerosis (SSc) digital vasculopathy, according to a study.

Use of ixekizumab (IXE) for 3 years in patients with axial spondyloarthritis (axSpA) is safe, which is consistent with the previously established long-term safety profile, reports a study. Treatment with IXE results in sustained improvement of disease activity through 156 weeks.

In a pooled, post hoc analysis of the AURA-LV and AURORA 1 studies, lupus nephritis (LN) patients with moderate-to-high baseline levels of proteinuria (UPCR* ≥2 to ≥3 mg/mg) who were receiving add-on voclosporin achieved higher renal response rates and earlier UPCR reductions vs those who were only treated with the control regimen.

Tocilizumab (TCZ) may be used as an alternative treatment to antitumour necrosis factor (anti-TNF) agents for patients with Behçet disease (BD)-related uveitis and neurological manifestations, a recent study has shown.

A phenome-wide association study (pheWAS) has found known and potentially new risk factors for gastrointestinal (GI) dysfunction in systemic sclerosis (SSc), which include drug classes such as opioid, antimuscarinic, and endothelin receptor antagonist, and antinuclear antibodies (ANAs) subgroup.

Cigarette smoking is independently associated with a higher prevalence of hip joint involvement in ankylosing spondylitis (AS), suggests a study.